Evidence map›Paper›PMID 40924325›Full record

ArticleJournal of neuro-oncology2025

The dynamic nature of frailty in metastatic spine disease patients.

Oludotun Ogunsola, Edward S Harake, Sean Smith, Michael Albdewi, Varun Kathawate, Sebele Ogunsola, William Jackson, Joseph Evans, Vikram Chakravarthy, Nicholas Szerlip

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oludotun Ogunsola *Department of Neurosurgery, University of Michigan, Ann Arbor, MI, USA.
Edward S Harake *University of Michigan Medical School, Ann Abor, MI, USA.
Sean SmithDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA.
Michael AlbdewiUniversity of Michigan Medical School, Ann Abor, MI, USA.
Varun KathawatePerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sebele OgunsolaWestern Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA.
William JacksonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Joseph EvansDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Vikram ChakravarthyThe Ohio State University Wexner Medical Center, Columbus, OH, USA.
Nicholas SzerlipDepartment of Neurosurgery, University of Michigan, Ann Arbor, MI, USA. nszerlip@med.umich.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFrailty measures are critical for predicting outcomes in metastatic spine disease (MSD) patients. This study aimed to evaluate frailty measures throughout the disease process.

methodsThis retrospective analysis measured frailty in MSD patients at multiple time points using a modified Metastatic Spinal Tumor Frailty Index (MSTFI). Scores were 0: "not frail," 1: "mild", 2: "moderate, and ≥ 3: "severe." Measurements were taken at cancer diagnosis, spine metastasis (SM) diagnosis, and 4-month intervals up to 2-years. The change in frailty distribution was described at the general cohort and patient levels. Two-year survival was assessed from baseline frailty status at SM diagnosis.

resultsThis study included 465 patients with an average age of 62.3 years (± 12.7), 33.8% female. Prostate cancer was most common (20.9%), followed by renal cell carcinoma (15.3%), non-small cell lung cancer (NSCLC, 13.5%), and others. Frailty changed dynamically, most significantly early in the disease. Initially, 79.4% were not frail; this dropped to 60.1% at SM diagnosis and to 42.7% at 4 months. Patients with short-term (4 month) data showed rapid frailty progression, with 57% becoming moderately to severely frail (p = 0.01), whereas 45% with long-term (24 months) data remained non-frail (p < 0.0001). Contributing factors included anemia (32.7%), electrolyte abnormalities (16.9%), and malnutrition (11.4%). Histological classification influenced frailty. Higher frailty scores at metastatic diagnosis correlated with worse 2-year survival outcomes (p: <0.001-0.04), underscoring frailty's prognostic significance.

conclusionFrailty is dynamic, with a potential early intervention point to maintain or reverse it. Further research is needed to assess which frailty measures are most dynamic and amenable to intervention.

Indexed as

FrailtySpinal NeoplasmsAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesFrailtyInterventionMetastatic spine diseasePatient managementSurvival

Identifiers

PMID40924325
PMCPMC12511197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.